Since 1926, the Guerbet Group has had a long-standing tradition as a pioneer in the research and development of medical imaging contrast media. Headquartered in Paris, France, Guerbet is a publicly traded company on Euronext Paris (segment B – mid caps) and a leader in medical imaging worldwide. Guerbet’s legacy actually begin in 1901 when Marcel Guerbet discovered the first iodinated organic contrast medium, known today as Lipiodol® (Ethiodized Oil) Injection. Our teams contribute to progress made in the diagnosis of major disease areas (cancer, cardiovascular, inflammatory and neurodegenerative diseases). Our novel and effective imaging solutions help to improve patient management throughout the world.